Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
1.24Debt to Equity Ratio
VS
Market
Sector
Industry
History
$ 0.8Close
$ 0.58 - $ 1.87 52-Week Range
Ticker Information
Ticker
CUECompany Name
CUE BIOPHARMA INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQCUE BIOPHARMA INC - Debt to Equity Ratio Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
CUE - D/E Historical data
| Date | Debt to Equity Ratio | Shareholders Equity | Total Liabilities |
|---|---|---|---|
| 6/30/2025 | 1.24 | $ 18.16M | $ 22.55M |
| 3/31/2025 | 2.38 | $ 6.58M | $ 15.67M |
| 12/31/2024 | 0.84 | $ 17.5M | $ 14.69M |
| 9/30/2024 | 0.77 | $ 25.37M | $ 19.44M |
| 6/30/2024 | 0.96 | $ 21.62M | $ 20.71M |
| 3/31/2024 | 0.8 | $ 30.04M | $ 23.91M |
| 12/31/2023 | 0.66 | $ 37.09M | $ 24.45M |
| 9/30/2023 | 0.61 | $ 42.67M | $ 26.22M |
| 6/30/2023 | 0.59 | $ 46M | $ 27.16M |
| 3/31/2023 | 0.48 | $ 55.02M | $ 26.66M |
Key Performance Insights, Last 5 Years
- CUE BIOPHARMA INC's latest trailing twelve months (TTM) D/E stands at 0.22.
- Over the past 5 years, CUE BIOPHARMA INC's average D/E has been 0.63.
- The median D/E for CUE BIOPHARMA INC during this period was 0.49
- CUE BIOPHARMA INC reached its highest D/E over the past 5 years at 2.38.
- The lowest D/E recorded by CUE BIOPHARMA INC in the same timeframe 0.22
CUE BIOPHARMA INC's D/E vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
D/E Benchmarks
Similar metrics to Liabilities:
- Debt to Assets Ratio - [Calculation] Debt to Assets measures the ratio between a company’s [Liabilities] and [Assets]. A high ratio might indicate more risk.
- Total Liabilities - [Balance Sheet] Total liabilities are the sum of all possible claims against the company. Common examples are [Debt], [Payables], deferred revenues, issued bonds, warranties, and tax liabilities.
- Current Liabilities - [Balance Sheet] The current (short-term) portion of [Liabilities] includes obligations that are due to be paid to creditors within one year, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
- Free Cash Flow to Debt - [Calculation] The Free Cash Flow to Debt ratio allows investors to judge a company’s financial stability. It represents the fraction of debt that could be repaid within one year if all of the free cash flow would be used to repay debt. It is calculated by dividing Free Cash Flow [FCF] by a company’s [Liabilities].
- Non-Current Liabilities - [Balance Sheet] The non-current (long-term) portion of [Liabilities] includes obligations that are due to be paid to creditors more than year in the future, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
Definition of Debt to Equity Ratio
[Calculation] Debt to Equity (D/E) measures the ratio between a company’s [Liabilities] and [Equity]. A high ratio might indicate more risk.Liabilities / Equity
(=) D/E D/E for CUE BIOPHARMA INC is calculated as follows: Liabilities [ $ 19.06M ] / Equity [ $ 87.55M ]
(=) D/E [ 0.22 ] CUE - Debt to Equity Ratio, Last 5 years
0.22
Minimum
Sep 30, 2020
2.38
Maximum
Mar 31, 2025
0.63
Average
0.49
Median
D/E Benchmark AnalysisMarket
The chart above depicts the distribution of D/E for companies in the Total Stock Market. The average D/E of the companies is 1.39 with a standard deviation of 1.31.
The following table provides additional summary stats:
D/E in the Market:
| filtered constituents | 3.3K |
|---|---|
| min | 0 |
| max | 6.05 |
| average | 1.39 |
| median | 0.98 |
| std | 1.31 |